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Human muscle-derived CLEC14A-positive cells
regenerate muscle independent of PAX7
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Skeletal muscle stem cells, called satellite cells and defined by the transcription factor PAX7,
are responsible for postnatal muscle growth, homeostasis and regeneration. Attempts to
utilize the regenerative potential of muscle stem cells for therapeutic purposes so far failed.
We previously established the existence of human PAX7-positive cell colonies with high
regenerative potential. We now identified PAX7-negative human muscle-derived cell colonies
also positive for the myogenic markers desmin and MYF5. These include cells from a patient
with a homozygous PAX7 c.86-1G > A mutation (PAX7null). Single cell and bulk tran-
scriptome analysis show high intra- and inter-donor heterogeneity and reveal the endothelial
cell marker CLEC14A to be highly expressed in PAX7null cells. All PAX7-negative cell
populations, including PAX7null, form myofibers after transplantation into mice, and regen-
erate muscle after reinjury. Transplanted PAX7neg cells repopulate the satellite cell niche
where they re-express PAX7, or, strikingly, CLEC14A. In conclusion, transplanted human cells
do not depend on PAX7 for muscle regeneration.
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Despite our knowledge about the existence of a highlyeffective muscle regeneration program, muscle wastingdisorders cannot yet be treated. Satellite cells are the
tissue-specific stem cells of skeletal muscle1. Following muscle
injury, satellite cells proliferate, differentiate, and fuse with
existing muscle fibers to form new muscle tissue. Satellite cells
also self-renew, thus securing their maintenance. The paired
homeobox transcription factor Pax7 characterizes myogenic
precursor cells, quiescent satellite cells and proliferating early
myoblasts. Based on experiments in mice and mouse mutants,
various functions of Pax7 were proposed and controversially
discussed, for instance, a role in the specification or the postnatal
maintenance of satellite cells2–4. Furthermore, conflicting reports
on the function of Pax7 in muscle regeneration exist5–9. In
addition, satellite cells expressing high levels of Pax7 were
reported to possess higher self-renewal capacity than Pax7-low
cells10. MYF5 is another transcription factor expressed in quies-
cent satellite cells. Myf5 may support myogenic commitment of
satellite cells11. Attempts to utilize the regenerative potential of
muscle stem cells for therapeutic purposes so far failed. Reasons
are the low number of satellite cells, 3–6% of all myonuclei, dif-
ficulties to expand them while at the same time satellite cells fuse
or go into senescence, the lack of migration from the injection site
in allogeneic settings12, and the lack of genetically corrected
autologous cells in muscular dystrophies. The CRISPR/Cas9
technology may now allow for precise gene editing in primary
cells. Finally, it is not clear which molecular markers define the
cell populations with high myogenic potential. CD133 cells,
PW1 cells and mesenchymal stem cells have all been proposed to
have myogenic potential, but at least in mice there is no muscle
regeneration without Pax7-positive satellite cells6–8.
Muscle cells derived from induced pluripotent stem cells are
also an option for therapeutic applications13–15, but translation
into clinics might be an only distant aim.
We aimed to evaluate the potential of primary human satellite
cells and to identify subpopulations suitable for muscle regen-
eration. Previously, we established a method to expand human
skeletal muscle-derived cells. These cells are grown out from
small human muscle fiber fragments (HMFF). They are trans-
plantable, and they contribute to muscle regeneration16. Here, we
further characterize such cells and identified a new PAX7-
negative myogenic cell population, characterized by CLEC14.
Regeneration efficiency of myogenic desmin-positive cell popu-
lations did not depend on the expression level of PAX7.
Results
Characterization of human PAX7-positive, PAX7-negative,
and PAX-null myogenic cell populations. Pure myogenic cell
populations (n= 103) were isolated from human muscle biopsy
specimens obtained from 25 different donors using manual dis-
section followed by hypothermic treatment (Fig. 1a; Supple-
mentary Tables 1 and 2). All cell populations were 100% desmin-
positive, but the percentage of nuclei that stained for PAX7
ranged from 0 to 98%. PAX7-positive (PAX7pos) cell colonies
were defined as 15 to 98% PAX7-positive nuclei; PAX7-negative
(PAX7neg) cell colonies had either 0% or 1% PAX7-positive
nuclei. MYF5 was present in similar proportions of cells, i.e., was
expressed independently of PAX7 (Fig. 1). We asked whether
PAX7neg cell populations differed from PAX7pos cells in regard
to their molecular profile and regenerative capacity. In addition,
we included in our investigation cell colonies with a PAX7-null
mutation. This patient carried a homozygous splice acceptor site
mutation in PAX7 c.86-1G > A, r.684_919del (NM_002584.2),
which resulted in an exclusion of exon 2 and a premature stop
codon in exon 3 (Supplementary Fig. 1, Supplementary Table 3
and 4)17. Other less likely pathogenic variants in the autozygous
regions are depicted in Supplementary Table 3 and were deter-
mined by whole-exome sequencing. We did not find any de novo
variant in exome of the index patient.
The 5-year-old girl presented with a congenital myopathy, rigid
spine, and respiratory insufficiency. A detailed clinical description
is provided (Material and Methods, Supplementary Fig. 1,
Supplementary Video). The muscle biopsy specimen, obtained
from M. rectus femoris, had no overt pathological alterations
(Supplementary Fig. 1), but lacked PAX7-positive cells in tissue
sections. Nevertheless, we identified cell colonies that grew out of
the muscle fibers in our HMFF-based culture system. These cell
colonies were desmin-positive, but did not express PAX7 mRNA
or protein (PAX7null) (Fig. 1b–d).
We compared mRNA expression levels of various myogenic
genes by qPCR in PAX7neg, PAX7null, and PAX7pos cells. In
PAX7null cells, PAX3-mRNA was ~10-fold upregulated. PAX
genes are crucial determinants of muscle development and PAX3
is the only other member of the gene family co-expressed with
PAX7 in muscle precursors. MYF5, a key transcription factor for
the myogenic lineage, was similarly expressed on mRNA and
protein levels in all colonies, indicating that MYF5 is expressed
independently of PAX7. NCAM1 and MYOD1 mark satellite cells
and myoblasts; both markers were strongly reduced in PAX7null
cells (Fig. 1c). We also measured key markers of interstitial
mesenchymal cell populations associated with some myogenic
potential like fibroadipogenic cells, Osr1-positive, PW1/Peg3-
positive cells, or mesangioblasts, respectively. (Fig. 1c; Supple-
mentary Fig. 2a; Supplementary Table 6). PAX7null, but not
PAX7neg or PAX7pos cells, expressed high levels of PDGFRa and
OSR1, indicating that they potentially have fibroadipogenic
character, but expression levels of CD29/ITGB1 were comparable.
PEG3/PW1 also was low in PAX7null cells.
Single cell and bulk RNA-Seq of human myogenic cell popu-
lations separated based on PAX7 expression. To gain further
insight into the character of the various cell types, we employed
single-cell sequencing (SCS) of a total of 66,000 single cells from
nine colonies. These included PAX7pos and PAX7neg colonies
from different donors (Donor A, C, G, H) as well as biological
replicates. (Fig. 2; Supplementary Figs. 4–7; Supplementary
Table 7). We sequenced an average of 5080 cells per population
with a mean depth of 4753 reads per cell, and identified on
average 1307 genes and 2305 transcripts (measured by UMIs) per
cell. In parallel, bulk-mRNA-sequencing was performed (Sup-
plementary Figs. 2c and 10d; Supplementary Table 8; Supple-
mentary Data File 1). We created an interactive online tool to
visualize expressed genes of interest in all cell populations https://
shiny.mdc-berlin.de/hummus_sc_XkZL9gHZE2UBwjGb/).
We found that SCS and bulk RNA-Seq highly reproduced
qPCR data in regard to the expression of myogenic genes like
PAX7, MYF5, MYOD1, NCAM1 (Figs. 1 and 2; Supplementary
Figs. 2c, 4–7). tSNE plot analysis showed that cells from all
analyzed colonies separated into different clusters. One of these
clusters corresponded to proliferating cells (MKI67, PCNA;
Fig. 2d; Supplementary Figs. 4–7), but others were identified
independently of cell cycle signatures. PAX7pos colonies from all
donors contained detectable amounts of PAX7 transcripts and
were clearly distinct from PAX7neg colonies of the same donor;
they also clustered differently than the cells of the PAX7null
patient (Fig. 2). When all PAX7pos (or PAX7neg) colonies from
different donors were directly compared, cell clustering was based
on the donor (Supplementary Fig. 7a, b). We found highly
expressed genes with no previous association to myogenic
progenitor cells, such as TFPI2, CLDN11, CLEC14A, COL6A3,
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and FHL1. Among these genes, CLEC14A was most abundantly
expressed in PAX7null cells as determined in bulk RNA-Seq,
qPCR, and by immunofluorescence (Supplementary Figs. 2c, 4a).
Regenerative capacity of myogenic cell populations separated
based on PAX7-expression. After having established the mole-
cular signatures of PAX7null, PAX7neg, and PAX7pos cells we
evaluated their myogenic potential. We determined fusion indices
in vitro and performed transplantation experiments in vivo.
Fusion indices did not differ between PAX7neg, PAX7pos, and
PAX7null cells with some variability within each group and
ranged between 20 and 73% without serum depletion in either
population (Fig. 3a, Supplementary Fig. 3, Supplementary
Table 2). In vivo, we used a xenograft model. We injected 1 × 105
cells into the irradiated anterior tibial muscle (TA) of immuno-
deficient NOG mice. Three weeks after transplantation, human
muscle fibers had generated from PAX7pos, PAX7neg, and
PAX7null populations as determined by human-specific anti-
spectrin and anti-lamin A/C antibodies (Fig. 3b). Quantification
of these experiments revealed that the number of human fibers as
well as the fiber diameters was similar in transplants derived from
either cell population (Fig. 3c). More strikingly, we found that
PAX7pos and PAX7neg cell colonies were able to repopulate the
satellite cell niche between sarcolemma and basal lamina of
muscle fibers, where they reexpressed PAX7 as assessed by
immunohistological staining of laminin, human laminA/C and
PAX7 (Fig. 3d). As expected, human muscle fibers derived from
PAX7null cells did not express PAX7. It therefore came as a
surprise that the satellite cell niche in human fibers derived from
PAX7null cells was populated with CLEC14A-positive cells
(staining with antibodies against laminin, human-specific lamin
and human-specific CLEC14A) (Fig. 3d). We also performed
reinjury experiments of irradiated and transplanted NOG mouse
TA muscle using the myotoxic agent cardiotoxin (CTX). Injury of
the irradiated muscles caused a severe atrophy of the TA muscles,
but human muscle fibers and PAX7-positive cells in a satellite cell
position were also detectable after injury. Remarkably, regenera-
tion took also place after transplantation of PAX7null cells, and
CLEC14A-positive cells were again observed in the satellite
cell niche after reinjury (Supplementary Fig. 3). These results
clearly show that human cells that are PAX7neg or PAX7null
can generate new muscle fibers. CLEC14A-positive cells, located
in a satellite cell position and generated in the absence of
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Fig. 1 Characterization of human desmin-positive, PAX7- negative cell populations. a Experimental design. Cell colonies grow out of human muscle fiber
fragments (HMFF) within 3 weeks after hypothermic treatment. b Absence of PAX7 transcripts in PAX7null cells. The PAX7 c.86-1G > A mutation in
PAX7null cells leads to deletion of exon 2 and a premature stop codon in exon 3. The PCR primers shown here recognize exons 4 and 5. PAX7neg-B cells
are derived from donors with intact Pax7 gene and also do not express PAX7. c Expression of markers of myogenic and interstitial cells assessed by qPCR in
PAX7null, PAX7neg, and PAX7pos cell colonies. All data were normalized to two reference genes and relativized to the mean of PAX7pos cells. The dotted
line at twofold and 0.5-fold represents our threshold for differential expression. d Myogenic cells derived from HMFFs were stained for PAX7, desmin, and
MYF5. PAX7-negative populations (PAX7null, PAX7neg) show no specific signal for PAX7 in immunofluorescence stainings. Cell lines are described in
Supplementary Table 2. Scale bars: 20 µm.
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PAX7, appear to represent an additional stem cell pool for
regeneration.
Characterization of CLEC14A-positive cells and their regen-
erative capacity. We characterized CLEC14A-positive cells in
greater depth. PAX7null cells were strongly positive for CLEC14A
(Fig. 4a). We then defined the abundance of CLEC14A-positive
cells in the spectrum of HMFF-derived, myogenic 100% desmin-
positive cell colonies from donors with functional PAX7 genes
(56 cell colonies, 24 donors,) (Supplementary Table 1) and found
that ~20% of these cell colonies contain CLEC14A-positive cells
(Fig. 4b). The distribution of PAX7pos and CLEC14A-positive
cells in all 56 colonies indicated that PAX7 and CLEC14A
expression was mutually exclusive (Fig. 4b). We confirmed this by
double-immunofluorescence, which directly demonstrated that
PAX7pos cells are negative for CLEC14A and vice versa (Fig. 4b).
When CLEC14A-positive cells were sorted by fluorescence-
activated cell sorting (FACS) and transplanted into NOG mice,
human muscle fibers formed just as efficiently as when trans-
planting PAX7neg cell populations (compare Fig. 3b, c with
Fig. 4d; Supplementary Fig. 8). Finally, we reexpressed PAX7 in
PAX7null cells using a lentiviral PAX7-GFP expression vector
and isolated transduced cells by FACS-sorting (Supplementary
Fig. 9). Induction of PAX7 drastically changed the molecular
profile of PAX7null cells, inducing MYOD1 and NCAM1, and
downregulating CLEC14A (Fig. 4c). MYF5 remained unaffected.
CLEC14A so far has only been described as an endothelial cell
marker. We therefore performed molecular profiling and
functional angiogenesis assays to elucidate possible endothelial
characteristics of the myogenic, CLEC14A-positive cells. PAX7-
null cells do not carry typical endothelial cell markers such as
PECAM1 or ERG1 (Supplementary Fig. 10a). Their transcrip-
tome clearly separates from HUVEC cells in principal component
analyses (Supplementary Fig. 10d). Functionally, formation of
tubes is observed with PAX7null as well as with PAX7neg
or PAX7pos cells (Supplementary Fig. 10b). PAX7null cells
depicted an unusual number of caveolae as would be expected in
endothelial cells (Supplementary Fig. 10c).
At last, we returned to human muscle sections of the PAX7null
patient to evaluate whether CLEC14A-positive cells are residents
of the human satellite cell niche. Indeed, we found that the
satellite cell niche in PAX7null muscle harbors resident cells that
are positive for CLEC14A, syndecan-4 and PAX3 (Fig. 4e). In
muscle sections from donors with wildtype PAX7, CLEC14A
in satellite cells was more difficult to detect. The expression
level in the presence of PAX7 is very low (Fig. 4b) and in
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immunofluorescent stainings cannot compete with the strong
surrounding signals from capillary endothelial cells. However,
single molecule FISH (smFISH) generated the appropriate
sensitivity to demonstrate that CLEC14A indeed is expressed in
human satellite cells (Fig. 4f). Therefore, the presence of
myogenic, desmin-positive, and CLEC14A-positive cell popula-
tions derived from HMFFs as well as mRNA expression in
satellite cells in situ provide two lines of evidence that CLEC14A-
positive cells belong to the normal spectrum of human muscle
cells with regenerative potential in satellite cell position.
Discussion
We report a human myogenic muscle stem cell, located within
the satellite cell niche, that is defined by CLEC14A and MYF5. C-
type lectin family 14 member A (CLEC14A) is a type 1
transmembrane protein specifically expressed and so far reported
in endothelial cells18. MYF5 is a well-known transcription factor
of the myogenic lineage downstream of PAX7. The novel cell type
can well be identified in the patient carrying the PAX7null
mutation, although it is not confined to this rare pathological
condition. CLEC14A-positive myogenic cells also exist in indi-
viduals with functional PAX7 genes. CLEC14A and PAX7
expression is mutually exclusive. It will be interesting to further
elucidate the mechanism on how the gene expression of PAX7,
MYOD1, MYF5, NCAM1, and CLEC14A are regulated and
intercalated with each other in human muscle stem cells. MYF5
expression appears to be regulated independently from PAX7,
MYOD1, and CLEC14A.
The patient with the PAX7null mutation displays features that
resemble the reported phenotype of Pax7-deficient mice2. As seen
in whole-body MRI, the patient had small but normal muscle
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patterning, indicating that all muscles had formed in develop-
ment. Pax genes are crucial for organogenesis, and Pax3 is the
only other member of the gene family co-expressed with Pax7 in
myogenic cells. PAX3 mutations in Klein–Waardenburg syn-
drome lead to distal muscle defects19, whereas a PAX7null
mutation, as shown here, predominantly affects axial muscle
raising the question as to whether these genes are differentially
expressed in satellite cells of different muscles. PAX3-positive
satellite cells define a subpopulation of muscle satellite cells that
are particularly resistant to stress20,21. PAX7null cells also express
PAX3. Head muscle formation is controlled by a distinct genetic
program not involving Pax3/7 in mice. The presence of the severe
congenital ptosis in the PAX7null patient indicates that the role of
PAX7 in head muscles needs further investigation.
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Apart from CLEC14A, a number of genes were highly
expressed in PAX7null cells that were not previously associated to
myogenic progenitor cells, such as TFPI2, CLDN11, COL6A3, and
FHL1. These genes are interesting for several reasons: First, these
gene expression signatures might provide further insight about
the unusual myogenic PAX7null cells. Tissue factor pathway
inhibitor-2 (TFPI2) is a serine protease inhibitor expressed
in vascular endothelium, and is required for cardiogenesis in
zebrafish22,23. CLDN11 is a marker of endothelial cell tight
junctions24,25. Thus, despite the fact that these cells express
myogenic markers like PAX3 and MYF5, they also express genes
typical for endothelial (CLEC14A, CLDN11) or fibroadipogenic
cells (PDGFRa and OSR1). Second, from a translational point of
view, it is interesting that mutations in COL6A3 and FHL1, both
highly expressed in PAX7null cells, cause phenotypically very
distinct muscle diseases (Ulrich congenital muscular dystrophy
and reducing body myopathy, respectively), both characterized by
rigidity of the spine and respiratory failure26–29, which are also
prominent findings in the PAX7null patient.
Our findings do not allow conclusions as to whether myogenic
cells from the PAX7null patient originate from embryonic
endothelial cells, but a lineage relation between these cells types
exists in development, and even in the adult endothelial cells30–32.
Lineage-tracing experiments are not possible within our setup.
Key markers of many cell types that have previously been shown
to contribute to muscle regeneration like PDGFRa, PDGFRb,
PEG3/PW1, OSR1, ITGB1/CD29, TCF4, TP53, and PROM1/
CD133 have been analyzed33–40. CLEC14A-positive myogenic
cells display features of FAPs because they express PDGFRa and
OSR1, but ITGB1/CD29 does not differ from PAX7pos cells. Also,
they do not differentially express PW1 or PDGFRb. They also do
not share the features of mesangioblasts (CD133) or endothelial
cells. Furthermore, in contrast to FAPs or mesangioblasts,
CLEC14A-positive myogenic cells inhabit the satellite cell niche.
Apart from CLEC14A, other endothelial cell markers such as
ERG1, PECAM, or VCAM were not expressed in CLEC14A-
positive human myogenic cells41,42. We conclude that there is an
overlap between features of CLEC14A-positive myogenic cells
and previously described cell populations, but CLEC14A apprears
to define a so far non-described population in human muscle.
In summary, human muscle fiber regenerate after transplan-
tation and after reinjury in the same abundance, independent of
the expression of PAX7. PAX7null cells with myogenic potential
express CLEC14A. CLEC14A-positive cells belong to the normal
spectrum in humans and are not confined to the rare patient
carrying the PAX7null mutation. They have myogenic and
regenerative capacity and could become relevant in cell therapies
involving muscle stem cells.
Materials and methods
Patients. HMFFs were prepared from muscle biopsy specimens. Research use of
the material was approved by the regulatory agencies (EA1/203/08, EA2/051/10,
EA2/175/17, Charité Universitätsmedizin Berlin). Informed consent was obtained
from the donors or the legal guardians.
Case report of patient with a homozygous PAX7 c.86-1G>A mutation
(PAX7null). The patient was a 5-year-old girl born to fourth degree con-
sanguineous parents (first cousins) of Kurdish origin, with no family history for
neuromuscular disorders. Her two younger siblings were healthy. Her mother
reported scarce fetal movements during pregnancy. She was born at term and
suffered from an amniotic infection syndrome requiring antibiotic treatment and
oxygen supply. She had congenital severe bilateral ptosis that required head
extension for upward gaze. She was bottle fed owing to poor suction. She had
normal spontaneous limb movements and started rolling over at 3–4 months of
age. She could not lift her head at ventral position and failed to crawl. She achieved
independent sitting at 5–6 months of age and standing position at 10 months. She
walked independently at 14 months of age and was able to climb stairs from two
years of age onwards. She fell frequently that was likely provoked by an impaired
downside field of view as she compensated her ptosis by head extension. In
addition, she developed increasing difficulties for stair climbing and required
pulling at the ramp and pushing on her upper legs with her arms. However, she
could climb walls independently as leisure activity. Walking became more difficult
with walking perimeter below one kilometer because of rapid fatigability. She
developed an increasing hyperlordosis. At the age of 5 years she developed a
respiratory insufficiency requiring short-term invasive assisted ventilation during a
respiratory infection. Nocturnal non-invasive-assisted ventilation was started to
compensate sleep disordered breathing and nocturnal hypoventilation. She had
normal cognitive and speech development and normal sensory abilities. Body
length was at 50th percentile (P.) at birth, 75th P. at 4 years and dropped to 25th P.
at near 6 years of age. Body weight fall from 15th P. at birth to under 3rd P. at near
6 years of age.
Clinical examination at near 6 years of age revealed global muscle hypotrophy,
rigid spine with hyperlordosis and mild scoliosis, scapular winging, and flattened
thorax (Supplementary Fig. 1, Supplementary Video). She had mild dysmorphic
facial features associated with severe bilateral ptosis, decreased orbicular oculi
strength without facial weakness. External eye movements were only limited for
extreme upwards gaze. Proximal lower limb strength was reduced, notably for
thigh flexion and adduction. Upper arm movements above 90° were nearly
impossible. She had prominent axial muscle weakness with profound neck flexor
and extensor weakness (head extension and flexion were impossible against
gravity). In contrast, sideward head movements were nearly normal. No muscle
weakness was noticed in distal segments.
Forced vital capacity (FVC) of 0.33 l was measured in sitting position,
corresponding to 35% predicted FVC (FVC%p). Ultrasonography revealed weak
diaphragmatic motion, diaphragm atrophy as well as lack of inspiratory diaphragm
thickening (Supplementary Video). Sensitive and motor nerve conduction studies
and repetitive stimulation were performed on upper limbs and did not reveal signs
of neuropathy or abnormal neuromuscular transmission (data not shown).
Whole-body muscle MRI (Supplementary Fig. 1, Supplementary Video),
compared with an age-matched child with no neuromuscular disorder, revealed
normal masticatory muscles and tongue. Occipital muscles were almost entirely
replaced by fatty-fibrotic tissue, with only small muscle bands persisting. At neck
level, levator scapulae muscles were well conserved, whereas dorsal neck, trapezius
superior, and sternocleidomastoideus muscles as well as head flexors persisted only
as residual bands. Shoulder girdle, upper limb, and hand muscles were normally
developed with no pathological signature. At body wall level, extrinsic back
muscles and intercostal muscles were extremely hypotrophic and largely immured
Fig. 4 CLEC14A is a marker for a human myogenic cell in satellite cell position. a CLEC14A- staining of PAX7null, PAX7neg, PAX7pos cells. PAX7null
cells are strongly positive for CLEC14A. Some PAX7neg cell populations from dornors with intact PAX7 gene are also CLEC14A-positive. Reconstitution of
PAX7null cells with a lentiviral PAX7 vector changed the expression profile of CLEC14A and NCAM (bottom line). Red, PAX7; green, CLEC14A; blue,
Hoechst. Bar 20 µm. b PAX7 and CLEC14A expression in PAX7neg cell colonies were mutual exclusive. Fifty-six cell populations from donors with intact
PAX7 genes were analyzed for expression of PAX7 (green) and CLEC14A (red). Cell colonies are either positive for PAX7 or for CLEC14A. Some colonies
contained both, cells that were either PAX7 or CLEC14A-positive. Staining for PAX7 and CLEC14A in “mixed” cell populations depicted mutually exclusive
expression. Scale bar: 20 µm. c Gene expression in PAX7null cells selected by FACS-sorting (see also Supplementary Fig. 9) after lentiviral PAX7
transduction determined by qPCR 3, 6, and 12 days after DOX induction. All data were normalized to two reference genes and relativized to the mean of
PAX7pos cell colonies. The dotted line at twofold and 0.5-fold represents the threshold for differential expression. d TA muscle section from a NOG mouse
3 weeks after transplantation of CLEC14Apos cells shows newly built human muscle fibers. Quantification reveals similar results as in Fig. 3b.
Quantification as in 3c, but without PAX7 analysis. Each dot represents one mouse grafted with PAX7neg-CLEC14Apos cells (n= 8). Scale bar: 20 µm.
e Staining for huCLEC14A, PAX3 and Syndecan-4 indicates cells in satellite cell position (arrows) in the muscle tissue of the PAX7null patient. Nuclei are
stained with Hoechst (blue). About 8% of nuclei were positive for CLEC14A and localized in a satellite cell position (133 nuclei analyzed). Scale bars: 10 µm.
f SmFISH for huCLEC14A in a frozen muscle section of a normal human donor. The red arrow indicates a nucleus in satellite cell position and the white one
a endothelial cell nucleus. Scale bar: 20 µm.
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in fatty-fibrotic tissue. Abdominal wall muscles were hypotrophic. At pelvic girdle,
gluteal muscles were hypotrophic at proximal level, whereas their distal portions
were missing altogether. Psoas and iliac muscles persisted only as small bands. At
thigh level, rectus femoris was well preserved, whereas other thigh muscles were
hypotrophic and replaced by fatty tissue to various extents, with notably severe
pathological changes noted for abductor femoris, the proximal part of vastus
lateralis and distal part of vastus medialis muscles. Lower leg muscles and feet
muscles were largely unaffected apart from some mild fatty infiltration of the soleus
muscles. Biplanar imaging of the skeleton using EOS system identified no
developmental skeletal abnormalities with notably normal skeletal elements of the
thorax and spine (Fig. 4c). However, EOS confirmed the presence of scoliotic and
hyperlordodic deformation of the spine together with a flattened thoracic cage.
Both parents were healthy and strictly normal at neurological examination. In
particular they had normal muscle bulk and strength. Whole-body MRI failed to
show any abnormality; the probands father featured a particularly well-developed
muscle bulk (data not shown).
Satellite cell cultures. HMFFs were prepared according to Marg et al.16 with
following modifications. Hypothermic treatment was performed at 5 °C and the
incubation time was restricted to 7days. Up to 24 cell colonies grow out from each
muscle biopsy. Selected colonies were frozen at − 155 °C for long-time storage.
Immunofluorescence LSM microscopy. Cells were grown on µ-Slides (eight-well,
ibidi) for 2 days, washed with phosphate-buffered saline (PBS) and fixed with 3.7%
formaldehyde. After permeabilization with 0.2% Triton X-100 (except CLEC14A-
and NCAM staining), the cells were incubated in 5% bovine serum albumin (BSA)/
PBS for 1 h. Primary antibodies were used as described in Supplementary Table 5
and incubated in 1% BSA/PBS for 3 h at room temperature (RT). After washing,
samples were incubated with Alexa 488-, Alexa 568-, or Alexa 647-conjugated
secondary antibodies (Thermo Fisher Scientific; each 1:500) and Hoechst 33258
(0.5 µg/ml, Sigma-Aldrich) for 1 h in PBS at room temperature. For Co-Staining:
Cells were stained first with CLEC14A as described. Afterwards the cells were
permeabilized with 0.2% Triton X-100 and the protocol for PAX7 was run
overnight.
Muscle samples (M. rectus femoris from the PAX7null patient or M. tib. ant.
from cell-transplanted NOG mice) were frozen in liquid nitrogen-cooled
isopentane and 6 µm-thick sections were cut with a Leica cryostat (CM 3050 S).
Fresh (PAX3 and PAX7) or frozen cryosections were fixed with 3.7% formaldehyde
(CLEC14A, PAX3, PAX7, and Syndecan-4) or aceton. Primary antibody incubation
was done overnight (CLEC14A, PAX3, PAX7 and Syndecan-4) or for 2 h
(Supplementary Table 5). Samples were imaged with a Zeiss LSM 700 confocal
microscope (Carl Zeiss MicroImaging GmbH) or an EVOS FL Cell Imaging System
(Thermo Fisher Scientific). Images were composed and edited in ZEN 2.3 (Carl
Zeiss Microscopy GmbH) and CorelDRAW 2017.
Single-molecule fluorescence in situ hybridization. SmFISH was performed with
10 µm- fresh-frozen human muscle sections according to the manufacturer’s
manual (ACD, 323100-USM/Rev Date: 02272019). To avoid over-digestion pro-
tease IV incubation time was reduced to 10 min. For CLEC14A mRNA- detection
RNAscope Probe -Hs-CLEC14A-C2 (ACD, Catalog number: 510761-C2) was used.
Differentiation assay. Muscle cell differentiation was done without a specific
differentiation medium. In all, 5000 cells per well were seeded on a 24-well plate in
skeletal muscle cell growth medium with fetal calf serum (FCS, Provitro). After
9 days in a humidified atmosphere containing 5% CO2 at 37 °C, cultures were fixed
and stained with an antibody against skeletal myosin (Supplementary Table 5),
nuclei were stained with Hoechst. The fusion index was determined by dividing the
number of nuclei within myotubes by the total number of nuclei counted. For each
sample at least 600 nuclei were counted.
Human PAX7 protein expression in human cells. The human PAX7-coding
sequence was purchased from DNASU Plasmid Repository (Clone:
HsCD00513858; NCBI Reference Sequence: NM_013945.2, bases 599–2155). The
original TAA Stop-Codon was inserted via PCR at position 2152. The PAX7-
coding sequence was inserted into the lentiviral backbone vector pINDUCER21
(ORF_EG) (gift from Stephen Elledge & Thomas Westbrook; Addgene plasmid
#469489)37 using the Gateway Cloning Technology (Life technologies). The Len-
tivirus was produced using the PLP1, PLP2, and VSV-G production plasmids
(Thermo Fisher Scientific) in HEK293TN cells. In total, 4 × 106 PAX7null cells
(5.2 × 103/cm2) were infected with a MOI of 7.8 and FACS-sorted (FACSAria
Fusion, BD Biosciences) 4 days after infection using a GFP reporter. Exogenous
PAX7 expression was induced 3 days after FACS-sort by 8 ng/ml doxycycline. Cells
were collected 3, 6, and 12 days after induction. Uninfected PAX7null cells were
cultured parallel to the lentivirus infection protocol and used as control.
Whole-exome sequencing. DNA was isolated from peripheral leukocytes. Whole-
exome sequencing (WES) was done in the index patient and in both her con-
sanguineous parents (WES trio). Exonic sequences and flanking intronic regions
were captured using the BGISEQ-500 whole-exome enrichment and sequencing
protocol43 yielding ≈ 75 Mio paired-end FASTQ reads. These were aligned to the
human GRCh37.p11 genomic reference with BWA-MEM v0.7.144. The mean
coverage was 130–154×, > 97% of the RefSeq positions were covered > 10×, and >
93% > 20×. After fine-adjustment, the raw alignments were called for deviations
from the reference in all coding exons and 50-bp flanking regions using GATK
v3.845. The resulting VCF file was analyzed with MutationTaster2 to assess
potential pathogenicity of all variants46. Variants were filtered for different
inheritance models. For the recessive inheritance model, we removed variants that
occurred > 30× in homozygous state in the gnomAD database (homozygote fre-
quency > 6.0E-05). In addition, owing to the consanguinity of the parents, we
performed an autozygosity mapping with the
HomozygosityMapper2012 software47 using the VCF-files of the family members.
Only variants were considered as pathogenic that were located in genomic regions
that were homozygous in the index patient, but not in her parents. These genomic
regions comprised a total of 227.8 Mbp. For the dominant inheritance model, we
removed variants that occurred > 25 × in the heterozygous state in the gnomAD
database (MAF > 1.0E-04). For the de novo model, we searched for variants present
in the index patient, but absent from both parents.
Beyond that we investigated virtual panels of genes that are associated with
diseases annotated with “rigid spine” (HPO:0003306) in the OMIM database.
Additional panels comprised n= 35 genes for “Congenital myasthenic syndrome”
and n= 101 genes for “Congenital myopathy”. Potentially disease-causing variants
were further assessed for their pathogenicity using the additional information
provided by MutationTaster2 at http://www.mutationtaster.org (accessed March
2019) and visually inspected using the IGV software downloaded from http://www.
broadinstitute.org/igv/.
Virtual gene panels. Panel 1: Muscle diseases annotated with “rigid spine” in
OMIM (n=24): ACTA1, ACVR1, BAG3, BIN1, COL6A1, COL6A2, COL6A3, DES,
EMD, FHL1, KY, LMNA, MGME1, NEB, ORAI1, POMT1, POMT2, RYR1, SELE-
NON, TNPO3, TOR1AIP1, TPM3, TRIP4, VAMP1
Panel 2: Congenital myopathy, Version 1.129 (n=101), Genomics England
PanelApp at https://panelapp.genomicsengland.co.uk/panels/225/: ACTA1, ACTN2,
AR, ATP2A1, BAG3, BIN1, CACNA1S, CASQ1, CAV3, CCDC78, CFL2, CHCHD10,
CNTN1, COL12A1, COL6A1, COL6A2, COL6A3, COL9A3, CPT2, CRYAB, DES,
DMPK, DMPK, DNAJB6, DNM2, DOK7, DYSF, ECEL1, EPG5, FAM111B, FKBP14,
FLNC, GFER, GNE, HACD1, HNRNPA1, HRAS, HTRA2, ISCU, KBTBD13,
KLHL40, KLHL41, KLHL9, KY, LAMP2, LDB3, LGI4, LMNA, LMOD3, MAP3K20,
MATR3, MEGF10, MICU1, MTM1, MTMR14, MT-TL1, MYBPC1, MYBPC3,
MYF6, MYH14, MYH2, MYH3, MYH7, MYH8, MYL1, MYMK, MYO18B, MYOT,
MYPN, NEB, NEFL, ORAI1, PIEZO2, PNPLA2, PUS1, RBCK1, RYR1, SCN4A,
SELENON, SLC25A4, SLC25A42, SPEG, SPTBN4, SRPK3, STAC3, STIM1, STIM2,
TIA1, TNNC2, TNNI2, TNNT1, TNNT3, TPM2, TPM3, TRIP4, TTN, VCP,
VMA21, VPS33B, YARS2, ZC4H2
Panel 3: Congenital myasthenic syndrome, Version 1.47 (n=35), Genomics
England PanelApp at https://panelapp.genomicsengland.co.uk/panels/232/: AGRN,
ALG14, ALG2, CACNA1A, CHAT, CHRNA1, CHRNB1, CHRND, CHRNE,
CHRNG, COL13A1, COLQ, DOK7, DPAGT1, GFPT1, GMPPB, LAMA5, LAMB2,
LRP4, MUSK, MYO9A, PLEC, PREPL, RAPSN, RYR1, SCN4A, SLC18A3, SLC25A1,
SLC5A7, SNAP25, SYT15, SYT2, TOR1AIP1, UNC13A, VAMP1
Targeted sanger sequencing for PAX7. Genomic DNA from patient PAX7null
was isolated from blood with Qiagen FlexiGene DNA kit (Qiagen) and amplified
using the Taq “all inclusive” PCR reaction kit (PeqLab). PAX7 primer sequences
based on NG_023262.1 are listed in Supplementary Table 4. Sequencing at genomic
DNA level was performed by Source Bioscience. CLC Genomics workbench (v9.5)
was used for sequence alignments.
RNA isolation, reverse transcription, and quantitative PCR. Total RNA was
isolated from human primary myoblasts and skeletal muscle tissue using
NucleoSpin RNA/Protein Kit (Marcherey-Nagel) and treated with DNAse for
genomic DNA removal. RNA quantity and purity were determined with a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). RNA was reverse
transcribed through the QuantiTect reverse transcription kit (Qiagen). All qPCR
experiments were performed according to the MIQE guidelines48 using KAPA
SYBR FAST qPCR MasterMix Universal (PeqLab) in the Mx3000P instrument
(Stratagene) (Primer sequences Supplementary Table 6). GAPDH and cyclophilin
A were used as reference genes. GAPDH normalized data were shown and were
equivalent to calculations using cyclophilin A. qPCR results were analyzed with
MxPro software (v4.1), calculated in Excel, and plotted using GraphPad Prism (v8).
Bulk RNA sequencing (RNA-seq). RNA Sequencing libraries were generated
using the NEBNext rRNA Depletion Kit and NEBNext Ultra Directional RNA
Library Prep Kit for Illumina (NEB). Libraries were sequenced using a MiSeq
system (Illumina) in paired-end mode (read length 75nt). HUVEC read counts
were obtained from GEO (SRR7549223, SRR7549223, SRR7549225). Pre-processed
RNA-Seq data were analyzed using CLC Genomics Workbench (v. 9.5, Qiagen)
with a workflow executing the following the steps: (1) quality read trimming
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(2) quality control (3) RNA-Seq analysis by aligning reads to the human reference
genome and transcriptome (GRCh38). All samples passed the RNA-seq quality
check (Supplementary table 8). Total read counts were normalized by transcripts
per million (TPM). CLUSTVis was used for heatmap and PCA generation. Read
counts, normalized count data (Supplementary Data File 1), and raw fastq files are
uploaded to GEO BioProject PRJNA481958.
Single-cell sequencing: drop-seq procedure, single-cell library generation, and
sequencing. The Drop-seq procedure49 allows cost-effective highly parallel
sequencing of single cells and detects 3′ ends of messenger RNA and long-
noncoding RNA molecules. Upon nanoliter droplet formation, individual cells are
co-encapsulated with individual, uniquely barcoded beads, and become lysed
completely. Released cellular RNA transcripts then hybridize via their polyA tails to
polyd(T) primers that are attached to uniquely barcoded beads carrying unique
molecular identifiers (UMIs). Nanoliter-droplets are collected and broken, and
transcripts reverse transcribed into complementary DNA (cDNA), amplified by
PCR and sequenced in bulk.
Monodisperse droplets of ~1 nl in size were prepared on a self-built Drop-seq
set up following closely the instrument set up and library generation procedures
invented by Macosko et al.49 with minor modifications as previously described45.
Frozen cells (~1 million) were thawed immediately before a Drop-seq run, and
subsequently kept on ice or handled in the cold. Usually, a small number of cells
was seeded into cell culture flasks and expanded for immunofluorescence staining
to ensure cell characterization after thawing. The remaining cells were centrifuged
at 150×g for 5 min, resuspended in phosphate-buffered saline pH7.2 supplemented
with 0.01% bovine serum albumin fraction V (Biomol, 01400) and 1 U/µl RiboLock
RNase inhibitor (Thermo Fisher Scientific, EO0381), centrifuged, resuspended
again, strained through a 35 µm nylon cell strainer (Corning, 352235), counted and
used for Drop-seq at a final input concentration of ~200 cells/µl. Cell viability was
assessed by Trypan blue staining and was between 70 and 90% in all cases.
Individual cDNA libraries ranged from ~1.0 to 1.7 kb in average size, indicating
good overall quality of RNA and cDNA molecules. Single-cell Drop-seq libraries at
1.8 pM (final insert size average ~700 bp) were sequenced in paired-end mode on
Illumina Nextseq500 sequencers with 1% PhiX spike-in for run quality control
using Illumina Nextseq500/550 High Output v2 kits (75 cycles). Read 1: 20 bp
(bases 1–12 cell barcode, bases 13–20 UMI; Drop-seq custom primer 1
“Read1CustSeqB”), index read: 8 bp, read 2 (paired end): 64 bp.
Computational methods in single-cell RNA-seq. Data processing, alignment, and
gene quantification: We chose read 1 to be 20-bp long, which sequences the cell
barcode at positions 1–12 and the UMI at positions 13–20, while avoiding reading
into the poly(A) tail. The remaining 64 sequencing cycles were used for read 2.
Sequencing quality was assessed by FastQC 2(v.0.11.2), while special attention was
paid to the base qualities of read 1 to assure accurate cell and UMI calling. We used
the Drop-seq tools v. 1.1245 to trim poly(A) stretches and potential SMART
adapter contaminants from read 2, to add the cell and molecular barcodes to the
sequences and to filter out barcodes with low quality bases. The reads were then
aligned to the reference genome hg38 (Ensemble annotation 84). Typically,
~75–80% of the reads were found to uniquely map to the genome; muti-mapping
reads were discarded. The Drop-seq toolkit was further used to add gene anno-
tation tags to the aligned reads and to identify and correct bead synthesis errors, in
particular base missing cases in the cell barcode. Cell numbers were estimated by
plotting the cumulative fraction of reads per cell against the cell barcodes and
calculating the knee point. The DigitalExpression tool49 was used to obtain the
digital gene expression matrix (DGE) for each sample.
Cell filtering and data normalization: For a first view of gene quantification and
basic statistics we used the R package “dropbead” (https://github.com/rajewsky-lab/
dropbead)46. We discarded cells expressing < 500 UMIs, or more cells in which the
mitochondrial encoding RNA was > 35%. We normalized the UMI counts for every
gene per cell by dividing its UMI count by the sum of total UMIs in that cell, and
multiplying it by the number of UMIs that the deepest cell contained. Downstream
analysis was performed in log space.
Clustering, t-SNE representation and marker discovery: We used Seurat50 to
identify highly variable genes, perform principal component analysis, identify the
most important principal components and use them for clustering and t-SNE
representation. Around ~1200 highly variable genes were identified and the first 20
principal components were used for the clustering and the tSNE representation.
We used Seurat’s function FindAllMarkers to find potential markers for each
cluster in an unsupervised manner.
FACS of CLEC14A-positive/negative cells. Cultured human primary myoblasts
were detached by incubating with 0.25% Trypsin-EDTA for 4 min at 37 °C. Cells
were collected in Skeletal Muscle Cell Growth Medium (SMCGM, Provitro) and
centrifuged for 5 min at 200×g. The resulting cell pellet was resuspended in ice-cold
sterile-filtered 1% BSA in PBS (staining buffer) and centrifuged again at 200×g for
5 min at 4 °C. Cells were resuspended in staining buffer containing Anti-CLEC14A
antibody (ThermoFisher #PA5-47677, conc. 0.2 µg/µl, dilution 1:50) and incubated
for 20 min at 4 °C. Cells were washed twice with ice-cold PBS and incubated for
15 min at 4 °C in staining buffer containing Alexa Fluor 488-conjugated donkey
anti-sheep antibody (ThermoFisher #A-11015, conc. 2 µg/µl, dilution 1:500). Fol-
lowing incubation with the secondary antibody, cells were washed twice with ice-
cold PBS, resuspended in 1 ml ice-cold staining buffer containing 100 µg/ml Pri-
mocin (InvivoGen #ant-pm-1) and transferred to FACS tubes with 40 µm cell
strainer caps to remove cell clumps. CLEC14A-positive and negative cells were
sorted using a BD FACSAria Fusion Cell Sorter. After sorting, cells were collected
and cultured for 2 days in SMCGM containing 100 µg/ml Primocin and two more
days in SMCGM only prior to transplantation.
Animal experiments. All animal experiments were performed under the license
number G0035/14 (LAGeSo, Berlin, Germany). In all, 5- to 7-week old male NOD.
Cg-PrkdcscidIl2rgtm1Sug/JicTac (NOG) or NOD.Cg-PrkdcscidIl2rgtm1WjI/SzJ (NSG)
mice were purchased from Taconic Biosciences or Charles River Laboratories,
respectively, 1 week before each experiment. They were kept under daily mon-
itoring at our specific pathogen-free animal facility with free access to food and
water, provided with hiding place and nest material. Hygienic monitoring was done
according to FELASA recommendations.
Intramuscular cell transplantation. Focal irradiation of the recipient hind limbs
was performed 2–3 days prior to cell transplantation as described16,51. In brief,
mice placed under 9 mg/ml ketamine–1.2 mg/ml xylazine anesthesia at a dose of
160 μl/20 g were treated with a single X-radiation dose of 16–18 Gy using a
CyberKnife image-guided robotic radiosurgery system. The radiation protocol was
calculated according to a computed tomography scan, with 0.75 mm slice thick-
ness, and was devised to deliver the desired dose in the three-dimensional target
area within ~2 min, sparing the adjacent body parts. Biafine lotion was applied on
the irradiated area following the procedure. For transplantation, mice were placed
under ketamine-xylazine anesthesia as described above. The skin area over the TA
muscle was shaved and disinfected and an 11 µl cell suspension in sterile PBS+ 2%
FCS solution was injected into the medial portion of the TA muscle using a 25 µL,
Model 702 RN SYR Hamilton Syringe coupled to a custom-made 20-mm long 26 g
small hub removable needle. Mice were monitored daily. In some mice we observed
skin redness and hair loss in the irradiated area at day 14–20 days post irradiation.
We applied Bepanthen lotion daily on the affected skin until the date of killing. For
the transplantation of PAX7null, PAX7neg, and PAX7pos cells, 105 cells were
injected into pre-irradiated TA muscles of NOG mice. For the transplantation of
CLEC14Apos and CLEC14Aneg cells, 5 × 104 cells were injected into pre-irradiated
TA muscles of NSG mice. For analysis, mice were sacrificed 21 days after cell
transplantation. TA muscles were cut in two halves following a transversal plane
with the cutting edge atop. Each half was separately mounted in gum tragacanth on
cork disks and frozen in liquid nitrogen-cooled isopentane. Frozen muscles were
stored at –80 °C.
Intramuscular cell transplantation followed by reinjury. In all, 5 × 104 cells were
injected in pre-irradiated TA muscles of NSG mice. At day 21 post transplantation,
40 μl of 10 μM cardiotoxin (CTX, Latoxan #56574-47-1) dissolved in sterile PBS
were injected in the medial portion of the TA muscle using an Omnican 50 insulin
syringe (B.Braun). All the mice developed skin lesions on the irradiated skin areas
starting at day 26–28 post irradiation (3–5 post-CTX) owing to a bacterial infec-
tion. They received a daily i.p. injection of enrofloxacin (BAYTRIL, 1.25 mg/ml
in 0.9% NaCl solution, 240 µl/30 g body weight) and caprofen (RIMADYL,
1.25 mg/ml in 0.9% NaCl solution, 120 µl/30g body weight) from day 7–9 after
CTX injection. The lesions resolved completely after the treatment and the mice
were kept on Metamizole (5mg/ml in drinking water) until the end of the
experiment without any further complications. Mice were sacrificed 49 days after
cell transplantation (28 days after CTX injection) and TA muscles were dissected
and frozen as described above.
Electrodiagnostic (EDX) examinations. EDX examination was performed using a
Keypoint device (Natus, Middleton, WI, USA). Motor nerve conduction was
measured in the median and ulnar nerves and data were interpreted referring to
standard norms52,53. To study sensory conduction, orthodromic median mixed
palmar nerve conduction was recorded and interpreted and referred to normal
values. To assess neuromuscular junction function, a train of six repetitive
supramaximal stimulations of the median nerve at low frequency (2 Hz) was
performed.
Sonography. Longitudinal diaphragmatic motion was bilaterally measured using
time-motion (TM), ultrasound (US) mode, and a 6MHz transducer (Logic E
ultrasound system, General Electric, Bethesda). Direct evaluation of diaphragmatic
inspiratory and expiratory thickness was bilaterally obtained by brightness-
modulation (B) mode measurements with a high frequency probe (12MHz) that
was positioned sagittally along the lower lateral chest wall at the so called
apposition zone.
MRI. The proband, her parents, and an age-matched control subject underwent
whole-body imaging on a free-bore 3T General Electric Discovery MR750w GEM
system (General Electric, Boston, MA, USA), which employs multiple phased-array
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surface receiver elements. In the whole-body configuration, subjects were wrapped
in a multi-coils and multi-elements network. Head and facial muscles were
explored by a head coil that is usually intended for brain imaging. Subject’s safety
was ensured by braces fitted to the table. The setup enabled a maximum combined
field of view (FOV) of 200 cm to assure a whole-body scan. Subjects were scanned
first in coronal orientation followed by axial orientation. Data acquisition was
completed in five to seven steps during subject’s passage from head to feed through
the magnet. In the coronal orientation, the series of images that were acquired
successively at an identical slice level, were automatically combined to generate a
single coronal composite view using the constructor’s optional software. No
manual realignment was needed. The selected imaging sequences were (i) 3D T1-
weighted imaging on a coronal plane with multi-stacks exploration of the body
from head to mid-thigh, and (ii) IDEAL T2 derived from three points DIXON
technique on axial plane with multi-stacks exploration from head to toes. Water
images, fat images and in- and out-phase images were available for each slice. The
recommended parameters for whole-body muscle imaging in diagnosis and out-
come measures of neuromuscular disorders were respected in term of spatial
resolution.
The maximal 500-mm FOV was large enough to scan all patients, including
those with an important body mass. The technique required precise patient
positioning with upper limbs lying close along or above the body. No paramagnetic
contrast agent was injected. No cardiac or respiratory gating was performed. A
multibreath-hold option was added to the thoracic sequence steps in spontaneously
breathing patients who could hold their breath.
Biplanar radiography. Biplanar radiographs were acquired with the EOS system
(Paris, France) in a standing position, using both the conventional low-dose
protocol54.
Electron microscopy. Samples were fixed with 2% (w/v) paraformaldehyde and
2.5% (v/v) glutaraldehyde in 0.1 M phosphate buffer. First, an initial fixation in
double strength fixative and cell culture media at 37 °C in a ratio of 1:1 was done
for 15 min Second, the solution was replaced with single strength fixative and
incubated for 2 h at room temperature. Samples were postfixed with 1% (v/v)
osmium tetroxide, dehydrated in a graded series of ethanol, and embedded in
PolyBed 812 resin (Polysciences, Inc., Germany). Ultrathin longitudinal sections
(60–80 nm) of the cell layer were stained with uranyl acetate and lead citrate, and
examined at 80 kV with a Zeiss EM 910 electron microscope (Zeiss, Oberkochen,
Germany). Acquisition was done with a Quemesa CDD camera and the iTEM
software (Emsis GmbH, Germany). Images were cropped with Adobe Photoshop.
HUVEC cell culture. HUVECs were from PromoCell and cultured in endothelial
cell growth medium 2 (PromoCell) in a humidified atmosphere containing 5% CO2
at 37 °C. Medium was changed three times per week and cells were passaged at
80–90% confluence.
Angiogenesis tube formation assay. We performed HUVEC tube formation
assay with angiogenesis µ-slides (IBIDI) as a well-established in vitro angiogenesis
assays to test for endothelial characteristics in PAX7null and PAX7 proficient
muscle cells. Endothelial cells are able to form capillary-like tubular structures on
growth factor-reduced basement membrane extracts. We followed the application
note 19 from IBIDI with some minor changes. In brief, we coated µ-slides with
10 µl growth factor-reduced Matrigel (Corning) and left it overnight covered with
endothelial cell basal medium PromoCell) in a humidified atmosphere containing
5% CO2 at 37 °C. Next day, 10,000 cells per well, five replicates per cell line, were
seeded in endothelial cell growth medium 2 containing 50 ng/ml FGF. Samples
were imaged after 6h with an EVOS FL Cell Imaging System. Tube formation was
quantified using the Angiogenesis Analyzer plugin for ImageJ.
Statistical analysis. All transplantation experiments were performed with four to
seven biological replicates (as indicated in each legend of the figures) and results
are presented as the mean. In all, 10–20 cryosections were analyzed per muscle and
per mouse. For qPCR analysis, we used two reference genes and provided data
against GAPDH. All statistical analysis and graphs were performed using Graph-
Pad Prism Software (version 8.0). Two-tailed t tests are detailed for each applicable
figure.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data sets generated during the current study are available from the corresponding
author on reasonable request. Whole-exome data, bulk RNA-seq data, and single-cell
sequencing data are available at. SRA accession: PRJNA481958. The SRA records will be
accessible with the following link after the indicated release date: https://www.ncbi.nlm.
nih.gov/sra/PRJNA481958. All source data underlying Figs. 1–4, and Supplementary
Figure 1–10 are provided in Source Data file.
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